R2 CAD Panel Conditions: Postmarket Clinical Efficacy Study, Data Reanalysis
This article was originally published in The Gray Sheet
Executive Summary
A postmarket clinical efficacy study of R2 Technology's ImageChecker CT computer-aided detection (CAD) system for lung nodules should be a requirement for FDA approval, the agency's Radiological Devices Panel recommended Feb. 3
You may also be interested in...
CAD Fetal Monitor PMA Trial Design Is Focus Of October Ob/Gyn Panel
FDA's Obstetrics & Gynecology Devices Panel will convene Oct. 25 to discuss pivotal study design requirements for fetal monitors that use computer-aided detection for risk assessment
CAD Fetal Monitor PMA Trial Design Is Focus Of October Ob/Gyn Panel
FDA's Obstetrics & Gynecology Devices Panel will convene Oct. 25 to discuss pivotal study design requirements for fetal monitors that use computer-aided detection for risk assessment
R2 ImageChecker Approval Launches CAD Lung Market; iCAD Preps To Join
FDA approval of R2 Technology's ImageChecker CT CAD system for lung nodules July 8 provides the firm with a comfortable head-start over competitor iCAD, which expects to launch its own system in 2005